Inotek Pharmaceuticals Corp. (extinct)

Inotek Pharmaceuticals Corp. (extinct)

Inotek Pharmaceuticals Corp. (extinct)

Overview
Date Founded

1999

Headquarters

91 Hartwell Avenue,2nd floor,Lexington, MA 02421

Type of Company

Private

Employees (Worldwide)

17

Industries

Pharmaceuticals
IT Consulting & Services
Retail: Drug Stores
Medical Support Services
Biotechnology

Company Description

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Contact Data
Trying to get in touch with decision makers at Inotek Pharmaceuticals Corp.? Subscribe today to access their professional contact information.
Executives & Employees

Chief Business Officer & Executive Vice President

Paths to Inotek Pharmaceuticals Corp.
Potential Connections via
Relationship Science
You
Inotek Pharmaceuticals Corp.
Recent Transactions
Details Hidden

Inotek Pharmaceuticals Corp. purchases Rocket Pharmaceuticals Ltd. resulting in a new company Rocket Pharmaceuticals, Inc.

Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Transaction Advisors
Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Escrow Agent

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Underwriter

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Chair, Life Sciences Practice

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Key Stats and Financials As of
Market Capitalization
$767M
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

Director-Drug Development at Lovelace Respiratory Research Institute

Details Hidden

Co-Founder at Inotek Pharmaceuticals Corp.

Details Hidden

MedImmune Ventures focuses on discovering, developing and commercializing promising developments in the biotechnology products sector. The firm targets investments in areas with strategic potential for MedImmune LLC and AstraZeneca including: (1) cardiovascular disease (2) gastrointestinal disease (3) neuroscience (4) oncology (5) infectious diseases (6) respiratory disease and (7) inflammation.MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies that discover and develop human therapeutics. They place particular emphasis on the fields of infectious disease, immunology and oncology. Their Funds are modality agnostic, investing in biologics, small molecules and vaccines. Investments range up to $30 million per company with average investments of about $7 million.